Evidence map›Paper›PMID 35215324›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Hesperidin-Loaded Lipid Polymer Hybrid Nanoparticles for Topical Delivery of Bioactive Drugs.

Rajendra Jangde, Gamal Osman Elhassan, Sulekha Khute, Deependra Singh, Manju Singh, Ram Kumar Sahu, Jiyauddin Khan

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Hesperidin from Orange Peel as a Promising Skincare Bioactive: An Overview.International journal of molecular sciences · 2024
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Rajendra JangdeUniversity Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur 492010, India.
Gamal Osman ElhassanDepartment of Pharmaceutics, Unaizah College of Pharmacy, Qassim University, Unaizah 51911, Saudi Arabia.
Sulekha KhuteUniversity Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur 492010, India.
Deependra SinghUniversity Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur 492010, India.
Manju SinghUniversity Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur 492010, India.
Ram Kumar SahuDepartment of Pharmaceutical Sciences, Assam University (A Central University), Silchar 788011, India.ORCID 0000-0001-5671-6591
Jiyauddin KhanSchool of Pharmacy, Management & Science University, Shah Alam 40100, Selangor Darul Ehsan, Malaysia.
Pandit Ravishankar Shukla University · INAssam University · INManagement and Science University · MYQassim University · SA

Funding

Science and Engineering Research Board EEQ-SERB -2017-000294
6 · The paper itself

Abstract

Hesperidin is a bioflavonoid constituent that among many other biological activities shows significant wound healing properties. However, the bioavailability of hesperidin when applied topically is limited due to its low solubility and systemic absorption, so novel dosage forms are needed to improve its therapeutic efficacy. The objectives of this study were to develop hesperidin-loaded lipid-polymer hybrid nanoparticles (HLPHNs) to enhance the delivery of hesperidin to endogenous sites in the wound bed and promote the efficacy of hesperidin. HLPHNs were optimized by response surface methodology (RSM) using the Box-Behnken design. HLPHNs were prepared using an emulsion-solvent evaporation method based on a double emulsion of water-in-oil-in-water (w/o/w) followed by freeze-drying to obtain nanoparticles. The prepared formulations were characterized using various evaluation parameters. In addition, the antioxidant activity of HLPHN 4 was investigated in vitro using the DPPH model. Seventeen different HLPHNs were prepared and the HLPHN4 exhibited the best mean particle size distribution, zeta potential, drug release and entrapment efficiency. The values are 91.43 nm, +23 mV, 79.97% and 92.8%, respectively. Transmission electron microscope showed similar spherical morphology as HLPHN4. Differential scanning calorimetry verified the physical stability of the loaded drug in a hybrid system. In vitro release studies showed uniform release of the drug over 24 h. HLPHN4 showed potent antioxidant activity in vitro in the DPPH model. The results of this study suggest that HLPHNs can achieve sustained release of the drug at the wound site and exhibit potent in vitro antioxidant activity.

Indexed as

DPPH modelemulsion solvent evaporationhesperidinhybrid nanoparticlessustained release

Identifiers

PMID35215324
PMCPMC8877258
OpenAlexW4214504989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.